Callio Therapeutics is pioneering the next generation of antibody-drug conjugates with a pipeline of dual-payload ADCs designed to overcome treatment resistance and drive deeper, more durable responses. While first-generation ADCs have transformed cancer treatment, most patients ultimately progress and have urgent need for better therapies. Powered by highly adaptable dual-payload technology, backed by top life science investors, and led by an experienced team with a track record of success, Callio Therapeutics is built to deliver better outcomes for patients.

Callio Therapeutics

Org chart

Teams

Offices